Markt für Ateminhalatoren – Erkenntnisse aus globaler und regionaler Analyse – Prognose bis 2031

  • Report Code : TIPRE00003093
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 254
Buy Now

Der Markt für Ateminhalatoren wird voraussichtlich von 31.144,56 Millionen US-Dollar im Jahr 2022 auf 43.446,19 Millionen US-Dollar im Jahr 2028 wachsen; Es wird geschätzt, dass von 2022 bis 2028 ein aCAGR von 5,7 % erreicht wird.



Ateminhalatoren werden zum Inhalieren von Arzneimitteln verwendet, die ein wesentlicher Bestandteil der Behandlung chronischer Lungenerkrankungen sind. Sie werden sowohl zur Vorbeugung als auch zur Behandlung von Verschlimmerungen dieser chronischen Krankheiten eingesetzt. Sie bieten den Vorteil, eine systemische Arzneimittelexposition zu vermeiden und gleichzeitig sicherzustellen, dass die Arzneimittel direkt in die Lunge gelangen. Zahlreiche Produkte verabreichen Medikamente direkt in die Atemwege, beispielsweise Trockenpulverinhalatoren, Dosierinhalatoren (MDIs), Vernebler und Weichnebelinhalatoren. Es wird erwartet, dass der Markt für Atemwegsinhalatoren aufgrund der steigenden Prävalenz von Atemwegserkrankungen wie Asthma, chronisch obstruktiver Lungenerkrankung (COPD), Mukoviszidose, Asthma-COPD-Überlappungssyndrom und anderen wachsen wird.



Strategische Erkenntnisse< /h3>

Einblicke in den Markt für Atemwegsinhalatoren



Die wachsende Akzeptanz generischer Inhalatoren treibt das Wachstum des Marktes für Atemwegsinhalatoren voran



Inhalierte Medikamente mit einer breiten Palette von Inhalationsgeräten sind die Hauptstütze der pharmakologischen Behandlung von Asthma und COPD. Patienten mit Asthma und COPD benötigen oft täglich einen oder mehrere Inhalatoren, um ihre Atemwege gesund zu halten. Daher sind medizinische Fachkräfte besorgt über den Wechsel zwischen Medikamenten, da dieser sich durch mangelnde Therapietreue und Missbrauch von Aerosolverabreichungsgeräten negativ auf die Krankheitskontrolle auswirken kann. Angesichts des zunehmenden Drucks auf die Gesundheitsbudgets und des gleichzeitigen Auslaufens von Patenten für etablierte Inhalationsbehandlungen werden weltweit mehrere generische Ersatzprodukte hergestellt und geliefert. Mehrere Inhalationsmittel, die zur Behandlung von Asthma eingesetzt werden, umfassen generische Formulierungen wie Albuterol, Levalbuterol, Ipratropium, Budesonid und Fluticason/Salmeterol. Die generischen Inhalatoren sind bioäquivalent zu den Markenversionen und haben die gleiche Wirkung auf den Körper. Die Zahl generischer Asthmainhalatoren nimmt aufgrund des Patentablaufs weiter zu. Am 3. März 2020 hat die Food and Drug Administration (FDA) generische Asthmainhalatoren und generisches inhalatives Kortikosteroidpulver zugelassen. Im April 2020 genehmigte die FDA einen generischen Inhalator auf Basis von Albuterolsulfat, um den Bedürfnissen von COVID-19-Patienten mit Atembeschwerden gerecht zu werden. Da immer mehr Generika auf den Markt kommen, ist ein stärkerer Wettbewerb zu erwarten, der wiederum zu geringeren Medikamentenkosten führt. Kostensenkungen können sich auch aus der Einführung eines „zugelassenen Generikums“ ergeben. Somit verbessert die zunehmende Akzeptanz von generischen Inhalatoren und Asthmamedikamenten die Medikamenteneinhaltung und treibt dadurch den Markt für Ateminhalatoren voran.



Produkttypbasierte Einblicke



Basierend auf dem Produkttyp, dem Markt für Ateminhalatoren ist in Vernebler, Dosierinhalatoren und Trockenpulverinhalatoren unterteilt. Das Segment der Trockenpulverinhalatoren ist weiter unterteilt in Mehrdosis-Trockenpulverinhalatoren und Einzeldosis-Trockenpulverinhalatoren. Das Segment der Dosierinhalatoren (MDI) ist weiter unterteilt in Druck-Dosierinhalatoren und angeschlossene Dosierinhalatoren. Das Segment der Vernebler ist in Druckluftvernebler, Mesh-Luftvernebler und Ultraschall-Luftvernebler unterteilt. Im Jahr 2022 hatte das Segment der Trockenpulverinhalatoren den größten Marktanteil. Es wird jedoch erwartet, dass das Segment der Dosierinhalatoren (MDI) im Prognosezeitraum die höchste CAGR verzeichnen wird.



Markt für Ateminhalatoren nach Produkttyp– 2022 und 2028



Technologiebasierte Einblicke



Auf der Grundlage der Technologie ist der Markt für Ateminhalatoren in manuell betriebene Inhalatoren und digital betriebene Inhalatoren unterteilt. Das Segment manuell betriebener Inhalatoren hatte im Jahr 2022 einen größeren Marktanteil und wird im Prognosezeitraum voraussichtlich eine höhere CAGR verzeichnen.



Erkenntnisse auf Basis von Krankheitsindikationen



Basierend auf Krankheitsindikationen Der weltweite Markt für Ateminhalatoren ist in Asthma, COPD, pulmonale arterielle Hypertonie und andere unterteilt. Das Asthmasegment hatte im Jahr 2022 den größten Marktanteil und wird im Prognosezeitraum voraussichtlich mit der höchsten CAGR wachsen.



Anorganische und organische Strategien wie Fusionen und Übernahmen werden von Unternehmen auf dem Markt für Ateminhalatoren in hohem Maße übernommen. Nachfolgend sind einige wichtige Marktentwicklungen aufgeführt:




  • Im September 2022 brachte Beximco Pharmaceuticals ONRIVA TRIO BEXICAP auf den Markt, eine Trockeninhalationskapsel. ONRIVA TRIO BEXICAP ist das Präparat aus Indacaterol (150 µg), Glycopyrronium (50 µg) und Mometason (160 µg). Es wirkt auf drei Arten, um Asthmasymptome zu kontrollieren. Indacaterol und Glycopyrronium tragen dazu bei, dass die Muskeln der Atemwege der Lunge entspannt bleiben, um eine Bronchokonstriktion zu verhindern, während Mometason hilft, Entzündungen zu lindern. ONRIVA TRIO BEXICAP ist als Erhaltungstherapie bei schwerem persistierendem Asthma indiziert.

  • Im Juni 2021 gab Cipla bekannt, dass es die endgültige Genehmigung für seinen abgekürzten New Drug Application (ANDA) für Arformoteroltartrat-Inhalationslösung 15 µg/2 erhalten hat ml von der US-amerikanischen Food and Drug Administration. Die Arformoteroltartrat-Inhalationslösung 15 µg/2 ml von Cipla ist eine generische therapeutische Äquivalentversion von Brovana von Sunovion Pharmaceuticals Inc. mit AN-Bewertung.

  • Im Februar 2022 gaben AstraZeneca und Honeywell ihre Pläne bekannt, bei der Entwicklung zusammenzuarbeiten von Atemwegsinhalatoren der nächsten Generation, die das Treibmittel HFO-1234ze verwenden, das bis zu 99,9 % weniger Treibhauspotenzial (GWP) aufweist als Treibmittel, die derzeit in Atemwegsmedikamenten verwendet werden.

  • Im Januar 2023 hat die FDA Airsupra [unter Druck] zugelassen Dosierinhalator (pMDI)] in den USA zur bedarfsgerechten Behandlung oder Vorbeugung einer Bronchokonstriktion. Airsupra ist ein erstklassiger, unter Druck stehender Dosierinhalator (pMDI), ein Kombinationsmedikament mit fester Dosis, das Albuterol, einen kurzwirksamen Beta2-Agonisten (SABA), und Budesonid, ein entzündungshemmendes inhalatives Kortikosteroid (ICS), enthält. in den USA.



Unternehmensprofile




  • AstraZeneca Plc

  • Beximco Pharmaceuticals Ltd.

  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.

  • GSK Plc

  • Koninklijke Philips NV

  • OMRON Corp

  • PARI Respiratory Equipment, Inc.
  • Teva Pharmaceutical Industries Ltd.

  • OPKO Health, Inc.



Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is meant by the respiratory inhalers market?

Respiratory inhalers are used to inhale drugs that are an essential part of treating chronic lung diseases. They are used both to prevent and treat exacerbations of these chronic diseases. They offer the advantage of avoiding systemic drug exposure while ensuring the drugs reach the lungs directly. Numerous products deliver drugs directly into the airways, such as dry powder inhalers, metered dose inhalers (MDIs), nebulizers and soft mist inhalers. The respiratory inhaler market is expected to flourish due to the rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others.

What are the driving factors for the respiratory inhalers market across the globe?

Key factors driving the market growth are rising cases of respiratory disorders and growing adoption of generic inhalers.

Which segment led the respiratory inhalers market?

The respiratory inhalers market, by product type, is segmented into nebulizers, metered dose inhalers, and dry powder inhalers. The dry powder inhalers segment held the largest market share in 2022 and is anticipated to register the highest CAGR during the forecast period (2022–2028).

Which technology segment held the largest revenue (US$ Mn) in the respiratory inhalers market?

Based on technology, the global respiratory inhalers market is divided into manually operated inhalers and digitally operated inhalers. The manually operated inhalers segment held the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.

Who are the key players in the respiratory inhalers market?

Companies operating in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd.; Boehringer Ingelheim International GmbH, Cipla Ltd.;GSK Plc, Koninklijke Philips NV, OMRON Corp, PARI Respiratory Equipment, Inc.; Teva Pharmaceutical Industries Ltd.; and OPKO Health, Inc..

What is the regional market scenario of the respiratory inhalers market?

Global respiratory inhalers market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is likely to continue its dominance in the respiratory inhalers market during 2022–2028. The US holds the largest share of the market in North America and is expected to continue this trend during the forecast period.

The List of Companies - Respiratory Inhalers Market

  1. AstraZeneca Plc
  2. Beximco Pharmaceuticals Ltd.
  3. Boehringer Ingelheim International GmbH
  4. Cipla Ltd.
  5. GSK Plc
  6. Koninklijke Philips NV
  7. OMRON Corp
  8. PARI Respiratory Equipment, Inc.
  9. Teva Pharmaceutical Industries Ltd.
  10. OPKO Health, Inc.  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports